Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Pfizer CTI Research Network Expands With NIH Collaboration

This article was originally published in The Pink Sheet Daily

Executive Summary

The partnership, announced Dec. 4, marks the first time a U.S. government agency has entered into a collaborative arrangement to conduct research through Pfizer’s Centers for Therapeutic Innovation network.

You may also be interested in...



AstraZeneca Has Stake In Three Of Nine NCATS Research Projects

Nine NIH National Center for Advancing Translational Sciences research projects involving repurposed investigational drugs will be funded with a total of $12.7 million and cover eight disease areas. In addition to AstraZeneca, compounds provided by Pfizer, Sanofi, Lilly and Janssen will be studied.

Pfizer’s CTI Shows Tangible Signs Of Progress In Its Junior Year

Pfizer’s Centers for Therapeutic Innovation program has grown in less than three years to include 24 academic partners. First drug candidate to emerge from the research model is expected to enter the clinic this year, and Pfizer’s investment in CTI has grown.

NIH Translational Science Center Becomes A (Cash-limited) Reality

NIH receives more than one-half billion dollars to finance activities of the National Center for Advancing Translational Science, which came into being when President Obama signed a consolidated fiscal 2012 appropriations bill Dec. 23. House and Senate members who negotiated the final bill cautioned that NCATS’ efforts to find ways to speed up drug development should not inhibit private efforts in the same arena.

Topics

Related Companies

Related Deals

UsernamePublicRestriction

Register

PS076790

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel